Posts

Roche licenses Simcere’s trispecific T-cell engager in deal worth up to $1.53 billion

Roche has signed an exclusive global licensing agreement with Simcere Zaiming for SIM0660, a trispecific T-cell engager targeting CD79a, CD19, and CD3. Simcere will receive $75 million upfront and may receive up to approximately $1.53 billion in total payments, including development and commercial milestones, plus tiered royalties reaching the double-digit range on future net sales. SIM0660 is intended primarily for B-cell malignancies, including newly diagnosed and relapsed/refractory B-cell lymphoma. Its broader potential could extend to other B-cell-mediated diseases, such as autoimmune disorders, although Roche’s current focus is oncology. The molecule is an early-stage asset: reports differ on whether it is described as preclinical or in early clinical testing, so its safety and efficacy remain unproven. The agreement marks another major China-originated licensing deal for Roche and adds to Simcere’s growing out-licensing track record. It follows Simcere’s earlier, rough...

GSK advances newer mRNA flu-vaccine formulation to Phase 3

Regeneron May Weigh Expanded Sanofi Partnership, RBC Says

Weave Bio and Takeda Expand AI Automation Across Drug-Development Regulatory Workflows

Wainua failure sharpens—but does not settle—the TTR silencer versus stabilizer debate

GSK advances dual-target mRNA flu vaccine to Phase III

Alumis plans biomarker-focused Phase III lupus trial after LUMUS miss

Novartis’ Rhapsido scores two Phase III wins in relapsing MS

ArsenalBio cuts most of its staff as it pivots to in vivo CAR-T

Roche Licenses Simcere’s SIM0660 in Deal Worth Up to $1.53 Billion

Novartis and BMS pause autoimmune CAR-T trials after serious immune-related events

Lilly’s Deal Spree Broadens Biotech Investor Paydays

Ascendis to Pay BioMarin Royalties in Global Yuviwel Patent Settlement